Abstract
Enhertu, a drug for people with HER2-low metastatic breast cancer, showed positive results in a Phase 3 trial. The antibody-drug conjugate, a joint effort of AstraZeneca and Daiichi Sankyo, reduced the risk of disease progression or death by 50% compared with chemotherapy . Shanu Modi, the trial’s principal investigator, said in a press release that this is the first demonstration of HER2-directed therapy providing “a survival benefit” to people with low HER2 expression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
